Overexpression of Sema3E and Sema5A in pilocytic astrocytoma

Alina Raza, Yvonne TM Tsang, Zhouying Yu, Adekunle Adesina, Kenneth Aldape, Ching C Lau, Kwong-Kwok Wong


We have previously found that Sema5A, a member of the semaphorin gene family, is up-regulated in pediatric pilocytic astrocytomas (PA) at the mRNA level by microarray analysis and real-time RT-PCR. By further analysis of the expression level of all 17 semaphorin genes in the microarray dataset, we found that Sema5A and Sema3E are the only two semaphorin genes that are highly up-regulated in pilocytic astrocytomas.  In this study, the up-regulation of Sema3E was further confirmed by real-time RT-PCR. Furthermore, the over-expression of both SEMA3E and SEMA5A proteins were also confirmed by Western blot analysis and immunohistochemistry.  Since pilocytic astrocytoma is characterized by extensive vasculature, co-immunofluorescent staining of both CD31 and SEMA3E (or SEMA5A) was performed. The result showed that a higher expression of SEMA3E was around the CD31 positive endothelial cells. Based on semaphorin’s function in angiogenesis and a higher expression of SEMA3E and SEMA5A around endothelial cells in these PA samples, these genes could be potential biological markers and anti-angiogenesis therapeutic targets for pilocytic astrocytomas.


Sema3E; Sema5A; astrocytoma; vasculature

Full Text:



Aarsen FK, Paquier PF, Reddingius RE, Streng IC, Arts WF, et al. Functional outcome after low-grade astrocytoma treatment in childhood. Cancer 2006; 106(2): 396–402. doi: 10.1002/cncr.21612.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97–109. doi: 10.1007/s00401-007-0243-4.

Fisher PG, Tihan T, Goldthwaite PT, Wharam MD, Carson BS, et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 2008; 51(2): 245–250. doi: 10.1002/pbc.21563.

Birlik B, Canda S, Ozer E. Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas. Neuropathol Appl Neurobiol 2006; 32(5): 532–538. doi: 10.1111/j.1365-2990.2006.00763.x.

Collins VP, Jones DTW, Giannini C. Pilocytic astrocytoma: Pathology, molecular mechanisms and markers. Acta Neuropathol 2015; 129(6): 775–788. doi: 10.1007/s00401-015-1410-7.

Stuer C, Vilz B, Majores M, Becker A, Schramm J, et al. Frequent recurrence and progression in pilocytic astrocytoma in adults. Cancer 2007; 110(12): 2799–2808. doi: 10.1002/cncr.23148.

Fernandez C, Figarella-Branger D, Girard N, Bouvier-Labit C, Gouvernet J, et al. Pilocytic astrocytomas in children: Prognostic factors--a retrospective study of 80 cases. Neurosurgery 2003; 53(3): 544–553; discussion 554–545.

Sutton LN, Cnaan A, Klatt L, Zhao H, Zimmerman R, et al. Postoperative surveillance imaging in children with cerebellar astrocytomas. J Neurosurg 1996; 84(5): 721–725. doi: 10.3171/jns.1996.84.5.0721

Due-Tønnessen BJ, Helseth E, Scheie D, Skullerud K, Aamodt G, et al. Long-term outcome after resection of benign cerebellar astrocytomas in children and young adults (0–19 years): Report of 110 consecutive cases. Pediatr Neurosurg 2002; 37(2): 71–80.

Wong KK, Chang YM, Tsang YT, Perlaky L, Su J, et al. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res 2005; 65(1): 76–84.

Rieger J, Wick W, Weller M. Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. Glia 2003; 42(4): 379–389. doi: 10.1002/glia.10210.

Artigiani S, Conrotto P, Fazzari P, Gilestro GF, Barberis D, et al. Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep 2004; 5(7): 710–714. doi: 10.1038/sj.embor.7400189.

Kantor DB, Chivatakarn O, Peer KL, Oster SF, Inatani M, et al. Semaphorin 5A is a bifunctional axon guidance cue regulated by heparan and chondroitin sulfate proteoglycans. Neuron 2004; 44(6): 961–975. doi: 10.1016/j.neuron.2004.12.002.

Oster SF, Bodeker MO, He F, Sretavan DW. Invariant Sema5A inhibition serves an ensheathing function during optic nerve development. Development 2003; 130(4): 775–784. doi: 10.1242/dev.00299

Chauvet S, Cohen S, Yoshida Y, Fekrane L, Livet J, et al. Gating of Sema3E/PlexinD1 signaling by neuropilin-1 switches axonal repulsion to attraction during brain development. Neuron 2007; 56(5): 807–822. doi: 10.1016/j.neuron.2007.10.019.

Gu C, Yoshida Y, Livet J, Reimert DV, Mann F, et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005; 307(5707): 265–268. doi: 10.1126/science.1105416.

Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003; 424(6947): 391–397. doi: 10.1038/nature01784.

Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest 2010; 120(8): 2684–2698. doi: 10.1172/JCI42118.

Yong LK, Lai S, Liang Z, Poteet E, Chen F, et al. Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. Oncotarget 2016; 7(52): 87431–87448. doi: 10.18632/oncotarget.13704.

Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64(6): 479–489. doi: 10.1093/jnen/64.6.479

Gutmann DH, McLellan MD, Hussain I, Wallis JW, Fulton LL, et al. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res 2013; 23(3): 431–439. doi: 10.1101/gr.142604.112.

Jones DT, Hutter B, Jager N, Korshunov A, Kool M, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 45(8): 927–932. doi: 10.1038/ng.2682.

Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013; 45(6): 602–612. doi: 10.1038/ng.2611.

Fangusaro JR, Onar-Thomas A, Young-Poussaint T, Wu S, Ligon AH, et al. A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study. J Clin Oncol 2017; 35: suppl; abstr 10504.

Sie M, de Bont ES, Scherpen FJ, Hoving EW, den Dunnen WF. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? Neuropathol Appl Neurobiol 2010; 36(7): 636–647. doi: 10.1111/j.1365-2990.2010.01113.x.

Gesundheit B, Klement G, Senger C, Kerbel R, Kieran M, et al. Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood. Med Pediatr Oncol 2003; 41(6): 516–526. doi: 10.1002/mpo.10308.

Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2014; 16(2): 310–317. doi: 10.1093/neuonc/not154.

Christensen C, Ambartsumian N, Gilestro G, Thomsen B, Comoglio P, et al. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res 2005; 65(14): 6167–6177. doi: 10.1158/0008-5472.CAN-04-4309.

Luchino J, Hocine M, Amoureux MC, Gibert B, Bernet A, et al. Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers. Cancer Cell 2013; 24(5): 673–685. doi: 10.1016/j.ccr.2013.09.010.

Worzfeld T, Offermanns S. Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov 2014; 13(8): 603–621. doi: 10.1038/nrd4337.

Jin Z, Chau MD, Bao ZZ: Sema3D, Sema3F, and Sema5A are expressed in overlapping and distinct patterns in chick embryonic heart. Dev Dyn 2006; 235(1): 163–169. doi: 10.1002/dvdy.20614.

Fiore R, Rahim B, Christoffels VM, Moorman AF, Puschel AW. Inactivation of the Sema5a gene results in embryonic lethality and defective remodeling of the cranial vascular system. Mol Cell Biol 2005; 25(6): 2310–2319. doi: 10.1128/MCB.25.6.2310-2319.2005.

Sadanandam A, Sidhu SS, Wullschleger S, Singh S, Varney ML et al: Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. Br J Cancer 2012; 107(3): 501–507. doi: 10.1038/bjc.2012.298.

Pineda D, Garcia B, Olmos JL, Davila JC, Real MA, et al. Semaphorin5A expression in the developing chick telencephalon. Brain Res Bull 2005; 66(4–6): 436–440. doi: 10.1016/j.brainresbull.2005.02.011.

DOI: http://dx.doi.org/10.30564/amor.v3i5.139


  • There are currently no refbacks.

Copyright (c) 2018 Alina Raza, Yvonne TM Tsang, Zhouying Yu, Adekunle Adesina, Kenneth Aldape, Ching C Lau, Kwong-Kwok Wong

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.